Introduction: Multiple sclerosis (MS) typically requires life-long management with
The most common free-text responses to ''Why are you satisfied with the BETACONNECT TM autoinjector?'' were ease of use (46%), less irritation/pain at the injection site (33%), and smoother injections (24%).
Features considered most useful were automated injections (98%), adjustable injection speed (98%), and adjustable injection depth (98%). Ninety-seven percent thought it was easy to know when an injection was complete and 95% agreed/ strongly agreed it was easy to learn to use the autoinjector. Seventy-three percent agreed that Electronic supplementary material The online version of this article (doi:10.1007/s40120-015-0036-y) contains supplementary material, which is available to authorized users.
INTRODUCTION
Multiple sclerosis (MS) is a chronic and debilitating autoimmune disease affecting the central nervous system, with a worldwide prevalence of approximately 33 cases per 100,000 individuals [1] . Typically, the first manifestation of MS occurs when patients are in their 20 or 30 s, and it is normal to live with MS for about 30 or 40 years [2, 3] . Medication for MS usually includes long-term management with disease-modifying therapies (DMTs) such as interferon beta-1b, which can alter the pathological immune responses associated with MS, prevent relapses, and slow disease progression [4] .
Other than the development of new treatments, improving the management of MS can focus on a number of factors, including the delivery systems of existing drug therapies. Many of the currently approved DMTs require patients to perform regular self-injections, which can be associated with injection site reactions, pain, and needle phobia or other injection anxieties.
However, the use and ongoing development of autoinjectors have the potential to reduce the incidence of injection site reactions [5, 6] , reduce needle phobia and patients' anxiety about self-administered injections [7] , and increase adherence [8] . This is supported by new autoinjector designs that could make the injection process easier, particularly for patients with visual, dexterity or cognitive problems (for example, by incorporating electronic reminders to overcome forgetfulness) [5, 6, 9] .
A variety of injection devices for many DMTs have been developed and evaluated with respect to patient satisfaction [10] [11] [12] [13] [14] [15] . However, the new fully electronic BETACONNECT TM (Bayer Pharma AG) autoinjector evaluated in the current study encompasses many advances in autoinjector design and technology as outlined in the following section, which may further enhance patient comfort, satisfaction and adherence, and is hoped to further improve management of MS.
Thus, the aim of the current study was to investigate patient satisfaction and preference for this new interferon beta-1b autoinjector. We hypothesized that patients would be more satisfied with the BETACONNECT autoinjector in comparison with other methods they used previously to inject interferon beta-1b. We also aimed to investigate the reasons underlying patient satisfaction.
METHODS

BETACONNECT TM Autoinjector
The BETACONNECT autoinjector ( Fig. 1 The open-ended free-text box allowed participants to describe their feelings about the device completely unaided, reducing the potential influence of the survey design. The answers provided were coded by frequency that they were mentioned. Patients were also asked to rate the ease of performing injections (rating from very difficult to very easy) and how confident they were in performing an injection with the BETACONNECT (rating from very unconfident to very confident). The survey was created and managed by an independent market research company, and funded by Bayer HealthCare Pharmaceuticals, Inc., Whippany, NJ, USA. Respondents were offered a gift card valued at €10 for their participation.
All procedures followed were in accordance with the 1964 Declaration of Helsinki and its subsequent revisions. Informed consent was obtained from all patients included in the study.
This article describes a non-interventional study, and so does not involve any new studies of human or animal subjects performed by any of the authors.
RESULTS
Demographic Characteristics
A total of 118 respondents with MS agreed to participate, and completed the survey. The demographic characteristics of survey Ergonomic design Allows ease of handling and one-handed operation: useful for patients with reduced manual dexterity (about 79% of patients with MS) [16] or short ' 'thumb reach' ' (particularly a problem for some women) [17] Intuitive user interface Simplicity and ease of use are considered important features by patients with MS [12] . May be helpful as about 65% of patients with MS have cognitive impairment which can accrue in all MS sub-types [18] Safety release Important owing to reduced manual dexterity in the majority of patients with MS (as noted above)
Automatic needle insertion/retraction and needle hidden at all times Avoidance of needle phobia and reduce the risk of inadvertent needle-stick injury [19] End-of-dose indicators (visible and audible) Considered important by patients with MS [12] Adjustable injection speed and depth Regarded as important features, and lack of control of injection process including speed and depth given as a reason for not using an injection device [12] Injection reminder Forgetting to take medications for MS is the most common reason for non-adherence to MS drug therapy [20, 21] MS multiple sclerosis participants are shown in Table 2 . Nearly three-quarters (72%) of respondents were female, average age was 47.2 years, and the majority (69%) had been using the autoinjector for more than 1 month. Before using BETACONNECT, the majority of participants had been administering interferon beta-1b
Bayer Pharma AG) or manual injection with a syringe (4%).
Overall Perceptions of BETACONNECT TM
The overall ratings for the autoinjector were very positive, with 90% of respondents stating that they preferred BETACONNECT to their previous injection method and 92% reporting that they were very confident or confident in their ability to perform an injection using the BETACONNECT autoinjector (Fig. 2) The features of BETACONNECT that were rated as most useful (i.e., rated ''useful'' or ''highly useful'') are shown in Fig. 4 . Features considered as most useful (by 98% of survey responders in each instance) were automated injections, adjustable injection speed, and adjustable injection depth. Features that help guide the injection process such as the self-check function (which communicates that the autoinjector is functioning and ready for use) and the end-of-dose indicator (signified acoustically and visually) were also rated as ''useful'' or ''very useful'' by more than 9 in 10 respondents using these features.
Ease of Use
Responses related to the intuitiveness and ease of use of the autoinjector were also favorable: 97% thought it was easy to know when an injection was complete and 95% agreed/ strongly agreed it was easy to learn to use the a Multiple selections were allowed to cover any previous injection method the patient had used, thus these percentages total more than 100% autoinjector (Fig. 5) . Likewise, 94% agreed/ strongly agreed that the lights and buttons are self-explanatory, and 91% that the light bar makes it easy to monitor the progress of an injection. Among those aware of the contact sensor (n = 110), 85% agreed/strongly agreed it 
Effect of BETACONNECT on the Patient Experience
Participants using the various features of BETACONNECT largely agreed they had a beneficial effect on their injection experience (Fig. 6) . Among those personalizing their injection depth (n = 57) and speed (n = 59), 88% and 81%, respectively, thought that these features make injecting more comfortable.
Moreover, 73% agreed that the quietness and effortlessness of the BETACONNECT autoinjector reduced their level of anxiety about injecting. BETACONNECT also received positive ratings regarding its ease of handling:
92% agreed that the size and shape of BETACONNECT makes it easy to handle during injections and 68% thought that BETACONNECT makes it easier to reach injection sites. Moreover, 67% agreed that the autoinjector decreases the level of injection site pain. These results also suggest that BETACONNECT may help improve compliance, as 80% of those using the reminder function thought they were less likely to miss an injection.
DISCUSSION
Interferon beta-1b is an injectable DMT with an established and favorable long-term safety and efficacy profile for patients with MS [22] [23] [24] . In addition, administration of DMTs using an autoinjector can reduce the number of adverse events such as injection site reactions, increase adherence to treatment, and improve patients' quality of life [6, 8, 25] . Whilst it is known that the use of an autoinjector is generally superior to manual injection for administering DMTs [6] , These issues may contribute to needle/injection phobia, and in fact a survey of patients with MS reported that among those using mechanical autoinjectors, most users (54%) were unsatisfied or only moderately satisfied with their device [14] . As such, there is considerable scope to improve patients' injection experience, with many of these needs being met by the development of autoinjectors such as BETACONNECT. BETACONNECT features a fully electronic silent injection process and a needle that is hidden before, during, and after injection. Nevertheless, it is particularly important to measure patient satisfaction with new autoinjectors, such as BETACONNECT, as increased treatment satisfaction is associated with better adherence, as shown by numerous studies covering a wide range of medical conditions and treatments, including MS [21, 26] . For patients with MS, satisfaction with treatment (odds ratio [OR] 1.54; 95% CI 1.20-1.98; P = 0.0007) and ease of injection (OR 1.47; 95% CI 1.15-1.87; P = 0.002) were independent predictors of DMT adherence [21] .
A patient satisfaction survey has recently been reported by Weller et al. [27] and forms the precursor to the current report. Weller et al. [27] surveyed the use of the BETACONNECT autoinjector in 1365 patients using a 13-question structured paper survey to gauge overall satisfaction with the device and the relative importance of its features. They found that 88% felt that the autoinjector was good or very good, 92% that it was helpful or very helpful, and 89% of respondents would most likely/probably recommend its use [27] . closer to an accurate patient experience than a reliance on structured questions and answers alone. Potential weaknesses of the current study are that it was performed in an uncontrolled setting and without a longitudinal follow-up, and had a relatively small sample size.
The overall results from the current survey show a preference for BETACONNECT over the previous device or method of injection and suggest that using the BETACONNECT autoinjector may increase satisfaction with treatment among patients on interferon beta-1b therapy. General impressions of using the BETACONNECT injector in the current survey were extremely favorable. These results are also in line with another study where ''overall convenience'' was cited by patients with MS as the most common benefit of using another autoinjector [29] , whereas in other surveys better control of needle depth and injection speed was the most common response given as a desirable feature of autoinjectors for MS therapies [12, 14] . It is interesting to note that less skin irritation/pain and smoother injection were the second and 
